

## Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day

**The company has a drug, ORY-2001, in Phase IIa clinical trial in Multiple Sclerosis**

Today, 30th May, is **World Multiple Sclerosis Day 2018**. Oryzon Genomics, a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, is developing **ORY-2001** for the treatment of Central Nervous System (CNS) diseases, like Multiple Sclerosis (MS). **At the end of October 2017 Oryzon received the approval from the Spanish Medicines Agency to start a Phase IIa clinical trial with ORY-2001 in MS, which is currently ongoing, with patient recruitment having started in January 2018.** This study is a randomised, double-blind, 36 weeks study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS). At the international conference on MS ACTRIMS Forum 2018, which took place in San Diego last February, the company reported new data on the efficacy of ORY-2001 in animal models for MS, showing that ORY-2001 significantly reduced the clinical score, improved motor activity, reduced inflammatory cell infiltration and improved axonal integrity. In addition to the Phase IIa study in MS, ORY-2001 is currently in another Phase IIa clinical trial, in Alzheimer's.

ORY-2001 is an orally administered, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule has been shown to reduce cognitive impairment and neuroinflammation in preclinical models, and exerts neuroprotective effects. LSD1 is an epigenetic modulator, which regulates histone methylation and modulates gene expression patterns. Epigenetic approaches to modify the progression of various neurodegenerative diseases, which focus on the production of changes in gene expression patterns in brain cells, have generated interest in the pharmaceutical industry.

**Multiple sclerosis is an autoimmune disease** that is caused by recurrent inflammatory attacks on the CNS due to a malfunction of the immune system, leading to neurological disability. Data from the World Health Organization (WHO) estimate that the global prevalence is 30 cases per 100,000 inhabitants and the estimated incidence is approximately 2.5 cases per 100,000 inhabitants. MS affects approximately 2.5 million people worldwide each year and is the most debilitating neurological disease in young adults.

**About Oryzon**

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. The company has offices in Spain and USA. For more information, visit [www.oryzon.com](http://www.oryzon.com).

**FORWARD-LOOKING STATEMENTS**

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

**US Contact:**

**The Trout Group**  
**Thomas Hoffmann**  
+1 646 378 2932  
[thoffmann@troutgroup.com](mailto:thoffmann@troutgroup.com)

**Spain:**

**ATREVIA**  
**Patricia Cobo/Luis Rejano**  
+34 91 564 07 25  
[pcobo@atrevia.com](mailto:pcobo@atrevia.com)  
[lrejano@atrevia.com](mailto:lrejano@atrevia.com)

**The Company:**

**Emili Torrell**  
**BD Director**  
+34 93 515 13 13  
[etorrell@oryzon.com](mailto:etorrell@oryzon.com)